Compare abrdn Income Credit Strategies Fund (ACP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs State Street SPDR S&P Biotech ETF — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while State Street SPDR S&P Biotech ETF trades at $162.48. The key difference: abrdn Income Credit Strategies Fund pays a 17.78% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, abrdn Income Credit Strategies Fund nearer its low. Which is the better fit depends on your goals.
| ACP | XBI | |
|---|---|---|
Market Cap | $656.21M | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $5.98 | $163.87 |
52-Week Low | $5.01 | $84.71 |
Dividend Yield | 17.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
XBI trades at $160.81, up 0.22% for the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF has surged approximately 17% over the past month, fueled by biotech sector momentum, AI-driven drug discovery advancements, and robust M&A activity. Analyst consensus remains neutral with a single hold rating, while recent news highlights strong performance relative to broader healthcare ETFs.
Outlook: XBI offers exposure to biotech growth catalysts including M&A and innovation, but high volatility and overbought conditions pose near-term risks. Long-term potential hinges on sector stability and pipeline successes, though investors face elevated beta and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
